VKTX: Obesity program VK2735 advances in phase III with broad market and manufacturing strategies in place
Lead obesity candidate VK2735 is advancing through phase III trials in both injectable and oral forms, with maintenance studies exploring less frequent dosing for improved patient adherence. Manufacturing and commercialization strategies are in place to ensure broad market access, while pipeline in…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.